- Home
- CHRS vs VIOT Comparison
CHRS vs VIOT Comparison
Compare CHRS & VIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- VIOT
- Stock Information
- Founded
- CHRS 2010
- VIOT 2014
- Country
- CHRS United States
- VIOT China
- Employees
- CHRS N/A
- VIOT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- VIOT Consumer Electronics/Appliances
- Sector
- CHRS Health Care
- VIOT Consumer Discretionary
- Exchange
- CHRS Nasdaq
- VIOT Nasdaq
- Market Cap
- CHRS 112.5M
- VIOT 92.8M
- IPO Year
- CHRS 2014
- VIOT 2018
- Fundamental
- Price
- CHRS $0.78
- VIOT $1.39
- Analyst Decision
- CHRS Buy
- VIOT
- Analyst Count
- CHRS 3
- VIOT 0
- Target Price
- CHRS $4.68
- VIOT N/A
- AVG Volume (30 Days)
- CHRS 1.5M
- VIOT 145.2K
- Earning Date
- CHRS 05-12-2025
- VIOT 03-25-2025
- Dividend Yield
- CHRS N/A
- VIOT N/A
- EPS Growth
- CHRS N/A
- VIOT N/A
- EPS
- CHRS N/A
- VIOT 0.13
- Revenue
- CHRS $272,251,000.00
- VIOT $290,307,298.00
- Revenue This Year
- CHRS N/A
- VIOT $15.62
- Revenue Next Year
- CHRS $19.78
- VIOT $12.98
- P/E Ratio
- CHRS $1.83
- VIOT $4.76
- Revenue Growth
- CHRS 19.87
- VIOT N/A
- 52 Week Low
- CHRS $0.66
- VIOT $0.75
- 52 Week High
- CHRS $2.43
- VIOT $2.38
- Technical
- Relative Strength Index (RSI)
- CHRS 40.90
- VIOT 51.58
- Support Level
- CHRS $0.74
- VIOT $1.24
- Resistance Level
- CHRS $0.82
- VIOT $1.49
- Average True Range (ATR)
- CHRS 0.07
- VIOT 0.08
- MACD
- CHRS -0.00
- VIOT 0.02
- Stochastic Oscillator
- CHRS 19.71
- VIOT 58.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About VIOT Viomi Technology Co. Ltd
Viomi Technology Co Ltd along with its subsidiaries provides Internet of Things (IoT) enabled smart home products through its platform. It has developed an IoT Home platform, consisting of an ecosystem of IoT Home portfolio, and home water solutions, together with a suite of complementary consumable products and small appliances and others. Its product offerings include Smart kitchen products like refrigerators, oven steamers, dishwashers, and gas stoves, Other smart products such as air conditioning systems, washing machines, water heaters, smart water kettles, interactive smart screens and other smart devices, and Home water solutions include self-branded and Xiaomi-branded smart water purifiers.